Pharmaceuticals

Following a year of record profits, Cipher Pharmaceuticals is renewing its share buyback program, signaling a strong belief that its stock is undervalued.

Biotech firm Ocubio adds commercial titan Jim Mazzo and clinical pioneer Dr. Eric Donnenfeld, signaling a major play to disrupt the ocular health market.

With fresh capital, the Swedish biotech is scaling its revolutionary platform that decodes cellular communication, fueling a major US expansion.

Biotech firm Scribe Therapeutics, co-founded by a Nobel laureate, is pioneering a new gene therapy for high cholesterol that silences genes, not cuts them.

With double-digit growth and key US acquisitions, ESTEVE is rapidly expanding. But it's the firm's B Corp status that may redefine success in pharma.

A triple awards ceremony honors brands moving beyond profit, celebrating ethical governance, Halal leadership, and sustainable growth as the new currency of excellence.

South Korea approves its first homegrown CAR-T therapy, a landmark achievement offering new hope for lymphoma patients with impressive response rates.

New Phase III data shows a dual-action drug delivers significant weight loss while targeting liver health, positioning it as a major new player in the market.

The clinical trial leader renewed a key global certification, signaling a new era of quality and trust that could accelerate breakthroughs in Alzheimer's.

Swedish firm Navinci launches its Omni kit, targeting the spatial interactomics market with a new tool to visualize protein networks directly in tissue.

A new alliance between AssureCare and Pillr Health will use AI and analytics to help hospitals manage soaring specialty drug costs and improve patient care.

TRexBio has dosed the first patient in a new trial for its novel drug, TRB-061, which aims to rebalance the immune system to treat atopic dermatitis.

As RNA therapies boom, a new enzymatic platform promises to solve critical manufacturing bottlenecks, making next-gen drugs more scalable and sustainable.

With a new General Counsel known for navigating complex deals, Cosette Pharmaceuticals signals a major push for acquisitions and portfolio growth.

Berlin-based Tacalyx is advancing its lead drug, TCX-201, to the clinic, targeting a novel class of antigens once thought impossible to drug.

With patient enrollment accelerating for its novel lung fibrosis drug, LTI-03, Rein Therapeutics signals progress in a field desperate for new options.

Seattle startup CounterX Therapeutics to present its novel overdose prevention drug at a top investor event, signaling new hope in the fentanyl crisis.

As cargo capacity shrinks and tensions rise, FedEx leverages new routes and digital tools to keep critical medical supplies moving across the Middle East.

A new campaign aims to save a major research hub, igniting a debate over its economic benefits, medical breakthroughs, and the future of animal testing.

Scottish biotech EnteroBiotix secures major funding to advance its gut therapy for IBS-C, offering new hope for a disease-modifying treatment.